Halozyme Therapeutics (HALO) Tops Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Halozyme Therapeutics (HALO) Tops Q1 EPS by 1c

Halozyme Reports First Quarter 2015 Financial Results

May 11, 2015 4:05 PM EDT

SAN DIEGO, May 11, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the first quarter ended March 31, 2015. Financial highlights include revenues of $18.7 million and a net loss of $15.1 million, or $0.12 per share, compared to revenues of $12.0 million and a net loss of $26.5 million, or $0.22 per share, for the first quarter of 2014.

"We continued to execute well in the first quarter against a focused strategy in oncology,... More